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TreatmentThe lack of clear interpretation of clinical and operational evidence on misoprostol use for postpartum
hemorrhage (PPH) in the community may jeopardize the realization of its full potential for improving
women's survival. This paper highlights the usefulness of misoprostol in addressing PPH in the community
within the limits of available research evidence. There is now substantial evidence to support the beneﬁcial
effects of 600 μg of oral misoprostol for PPH prevention in the community, with a trend toward better
protection against severe PPH morbidity, and particularly when administered by less skilled or lay caregivers.
Although there is tangible evidence to show that 800 μg of sublingual misoprostol has important beneﬁts for
PPH treatment where there is no access to oxytocin, there is presently no direct evidence to indicate that less
skilled or lay caregivers can safely use it to treat PPH in the community. Operational research evidence
indicates that advance community distribution of misoprostol to pregnant women for postpartum self-use is
a feasible strategy to ensure availability of the drug at the time of birth. The evidence is, however, limited by
its quality to establish whether the beneﬁts of such a strategy truly outweigh the potential harms. It is time
for the international community to focus on improving PPH-related outcomes by scaling up what is currently
guided by hard evidence and join forces to address unanswered questions through high-quality research.
© 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.1. Introduction
As the deadline for the United Nations' Millennium Declaration
draws near, the persistently high burden of maternal ill health and
death in low- and middle-income countries demands a revision of the
strategies to improve women's survival by the international commu-
nity. There is increasing interest in ﬁnding alternative ways to expand
access to low-cost, evidence-based technology that could improve
women's health in rural and hard-to-reach areas in low-resource
countries. Tackling postpartum hemorrhage (PPH), the leading cause
of maternal death, through such complementary strategies—from the
preventive and treatment perspectives—has taken a top priority. It has
become clear that after several decades of promoting the conventional
uterotonics for PPH prevention and treatment, achieving the desired
impact has remained challenging, as they are not available or feasible
for use in all settings. This gap has drawn attention to misoprostol,
a synthetic prostaglandin E1 analog, which offers the opportunity
to expand uterotonic coverage to settings where women rely only on
physiologic control of postpartum blood loss.
Misoprostol is a potent uterotonic with some remarkable advan-
tages over conventional uterotonics in resource-poor settings. It does
not necessarily require skilled personnel for its administration sinceeration of Gynecology and Obstetrics.it is available in tablet form. It requires no cool storage facility to
maintain its potency and is comparatively more stable at room
temperature, thus has a long shelf life even in temperate climates. The
adverse effects are frequent, but often do not require any treatment.
Many international health bodies recommend misoprostol as a
reliable alternative where oxytocin or ergometrine is not available or
where their use is not feasible [1,2]. The World Health Organization
(WHO) also acknowledged its critical role in improving maternal
health by including it in its Model List of Essential Medicines for
PPH prevention in 2011 [3]. These endorsements were the result of
the growing body of research regarding the effectiveness, safety, and
acceptability of misoprostol for PPH prevention and treatment.
Despite the consensus that misoprostol is a ﬁrst-line alternative
where conventional uterotonic use is not practicable, expanding its
use to places where it could make a difference to women's survival
has been slow. This unimpressive transition from research ﬁndings to
clinical policies, programs, and practices has been attributed to many
factors: its wide range of indications (including controversial ones
such as abortion), its nonregistration for PPH in many countries,
the lack of guidelines and provider training, concerns regarding its
adverse effects, and misconceptions about the potential effects on
promoting home births at the expense of institutional delivery [4].
Central to these challenges is the lack of clarity in the interpretation
given to the available clinical and operational research evidence
on misoprostol use for PPH in the community by various interest
groups. While some are promoting unhindered rollout of misoprostolPublished by Elsevier Ireland Ltd. All rights reserved.
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[5–7], there are also those calling for caution based on insufﬁcient
evidence on the value and safety of such an approach [8,9]. The
increasing volume of literature and sometimes conﬂicting evidence
regarding misoprostol use for PPH in different settings has not helped
matters. Getting past the obstacles limiting misoprostol's potential to
effectively address the uterotonic coverage gap in the community
requires reconsideration of the available answers to some fundamen-
tal research questions and presenting a balanced interpretation that
is critical for decision making by policy makers. In the present paper,
the evidence regarding misoprostol's effectiveness and safety in the
community setting is summarized against the background of contex-
tual issues relating to when and where it could be given, who could
give it, and whether it is safe to provide it in advance to pregnant
women for self-use after birth.
2. Is misoprostol effective and safe for preventing and treating
PPH in the community (where there is no access to
conventional uterotonics)?
2.1. Misoprostol for prevention
One reason for the initial hesitation in adopting misoprostol as a
useful uterotonic agent is traceable to the results of earlier randomized
controlled trials comparing misoprostol with no treatment in hospital
settings. These trials conducted in the late 1990s and early 2000s
showed inconsistent results regarding severe PPH and other indicators
of blood loss with 400–600 μg oral or 400 μg rectalmisoprostol [10–15].
This uncertainty has now been resolved with the results of 3 well-
conducted and relatively large randomized controlled trials comparing
600 μg of oral or sublingualmisoprostol with placebo in primary care or
home delivery settings. These trials, which were conducted in Guinea
Bissau [16], India [17], and Pakistan [18] between themid- to late 2000s,
consistently showed beneﬁcial effects of misoprostol over no treatment
for PPH prevention. A meta-analysis of the ﬁndings conducted for the
present paper showed that misoprostol resulted in 24% and 41%
reductions in the incidence of PPH (Fig. 1) and severe PPH (Fig. 2)
compared with placebo, respectively. Subgroup analyses by the skill
level of caregivers providing misoprostol in these studies indicate
that the effects increased from that of uncertain beneﬁts to 34%
reduction for PPH (Fig. 1) and from 34% to 56% reduction for severe
PPH (Fig. 2), between its administration by qualiﬁed midwives and
lower-level health workers, respectively. These ﬁndings support the
positive effects of misoprostol on PPH morbidity, particularly on heavyFig. 1. Randomized trials of the effect of 600 μg of oral or sublingual misoprostol versus p
settings, subgrouped by the skill level of caregivers.blood loss, and especially when used by less-skilled health providers in
the community setting. What remains uncertain, however, is whether
this improvement in PPH morbidity is sufﬁcient to reduce the risk
of maternal death in the community as the 3 trials collectively lack
sufﬁcient power to detect such a difference (1/1675 [0.06%] vs 1/1722
[0.06%]; RR 1.00, 95% CI, 0.14–7.07) (Fig. 3).
In view of the disparity between the ﬁndings of hospital- and
community-based trials, it appears that the efﬁcacy of misoprostol
becomes apparent as one moves from hospital to primary care and
home birth settings. It is reasonable to explain this heterogeneous
ﬁnding by the variations in the available number and skills of
caregivers in addition to routine care and delivery practices during
the third stage of labor. Adjunct care and other precautionary
measures during the third stage that are based on prelabor risk
assessment are only likely in hospital settings where skilled pro-
fessionals are available. It is possible that such added skills and
care reduce the baseline risk of PPH and thus increase the sample
size required to demonstrate beneﬁcial effects of misoprostol. The
potential effect of variation in delivery practices is demonstrated in
the subgroup analyses of the community-based misoprostol versus
placebo trials. The beneﬁcial effect of misoprostol with respect to
PPH (17% to 47% reduction; Fig. 4) and severe PPH (36% to 80%; Fig. 5)
becomes more appreciable when the effect of misoprostol over
placebo is compared between trials where caregivers were trained
in and permitted to offer active management of third stage of
labor (AMTSL) and those where expectant management was prac-
ticed. This differential effect has signiﬁcant positive implications
for settings where lower-level health workers without skills in AMTSL
attend births.
With regard to safety concerns, women who receive misoprostol
are likely to experience some adverse effects, notably shivering,
pyrexia, and gastrointestinal symptoms such as nausea, vomiting, and
diarrhea. Three community-based placebo-controlled trials involving
3397 women [16–18] showed that misoprostol was associated with a
very low incidence of vomiting (1.5%) and diarrhea (1.3%), which was
similar to their frequencies in the placebo arm. It was, however,
signiﬁcantly associated with shivering (39.6% vs 14.0%; RR 2.77, 95% CI,
2.44–3.14) and pyrexia (6.9% vs 1.6%; RR 4.35, 95% CI, 2.88–6.57). These
adverse effects are self-limiting and often subsidewith reassurance and
symptomatic treatment that can be offered by lower-level caregivers.
It is reassuring to note that severe maternal morbidity or maternal
death was extremely rare, with 1 reported death among 1675 women
(b0.1%) who received misoprostol in the 3 community-based trials,
which is similar to that reported in hospital settings [19].lacebo on postpartum hemorrhage (blood loss >500 mL) in community/primary care
Fig. 2. Randomized trials of the effect of 600 μg of oral or sublingual misoprostol versus placebo on severe postpartum hemorrhage (blood loss >1000 mL) in community/primary
care settings, subgrouped by the skill level of caregivers.
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As expected, the evidence regarding the usefulness of misoprostol
for PPH treatment in the community does not enjoy the same
acceptance and conﬁdence as its use for PPH prevention. This is
mainly because treatment of PPH with uterotonics requires the
skill to diagnose atonic PPH—a skill that is considered to be beyond
the capacity of most caregivers at the community level. However,
exploring other pragmatic treatment options for PPH in the commu-
nity is valuable since intravenous oxytocin, the gold standard for PPH
treatment, is an unrealistic choice in the short to medium term.
Interestingly, a Cochrane review evaluating misoprostol as a treat-
ment option for PPH included two hospital-based, placebo-controlled,
randomized trials that assessed the effects of misoprostol in women
who had received routine treatment with conventional oxytocics
[20]. These trials showed some beneﬁts regarding blood loss greater
than or equal to 500 mL within 1 hour (RR 0.57; 95% CI, 0.34–0.96),
but somewhat equivocal results with regard to the use of additional
uterotonics, blood transfusion, evacuation of retained products,
hysterectomies, and maternal death. Although the review authors
concluded that there is insufﬁcient evidence to demonstrate the
beneﬁts of such intervention, the ﬁndingswould have had little value in
a community setting where initial treatment of PPH with conventional
uterotonics is not feasible, even if it did.
While the best evidence regarding the value of misoprostol for
PPH treatment in the community could be derived from randomized
controlled trials comparing misoprostol with placebo or usual care
in such a setting, such a trial has yet to be conducted. This is not
surprising considering the logistic and ethical challenges that such a
trial would face. Therefore, evidence on the usefulness of misoprostol
for PPH treatment has been largely from a recent hospital-based
randomized trial involving 978women diagnosedwith PPH in Ecuador,
Egypt, and Vietnam that assessed the noninferiority of 800 μg ofFig. 3. Randomized trials of the effect of 600 μg of oral or sublingual misoprostsublingual misoprostol to intravenous oxytocin in womenwho had not
been previously exposed to oxytocin [21]. The ﬁndings showed that
active bleeding was controlled within 20 minutes in 440 (90%) women
givenmisoprostol alone and 468 (96%) given oxytocin (RR 0.94; 95% CI,
0.91–0.98); additional blood loss of 300 mL or greater after treatment
occurred in 147 (30%) women receiving misoprostol and 83 (17%)
receiving oxytocin (RR 1.78; 95% CI, 1.40–2.26). Although the study
showed that oxytocin is clearly more effective than misoprostol for
PPH treatment, it expressed the potential performance of misoprostol
compared with no treatment and identiﬁed its suitability as a ﬁrst-line
treatment alternative where oxytocin use is not feasible.
Safety concerns regarding the tested dose of misoprostol for PPH
treatment in the community can be evaluated within the context of
the same noninferiority trial [21]. Nausea and vomiting were more
common with the 800-μg dose than expected with the 600-μg dose,
occurring in 15% and 5%, respectively. Shivering occurred in 47% and
fever in 44% of women who received misoprostol for treatment,
which was close to 3 and 8 times as frequent, respectively, as in those
who received intravenous oxytocin. While these adverse effects
might cause considerable discomfort for the women, none of them
was life threatening. It is reassuring to note that there were no
hysterectomies or maternal deaths among women in both compar-
ison groups. Compared with the consequences of PPH, these common
adverse effects may be an acceptable price to pay in settings where no
other option currently exists.
3. Should misoprostol be used in the community setting as a
substitute for conventional uterotonics?
It is important to consider this question as situations may arise
where the choice of misoprostol might be considered an attractive
option for its logistical advantages even when oxytocin or ergome-
trine is available. A recently updated Cochrane review that includedol versus placebo on maternal death in community/primary care settings.
Fig. 4. Randomized trials of the effect of 600 μg of oral or sublingual misoprostol versus placebo on postpartum hemorrhage (blood loss >500 mL) in community/primary care
settings, subgrouped by the third stage of labor practice.
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between 400 μg and 600 μg of oral misoprostol with oxytocin,
ergometrine, or a ﬁxed-dose combination of the two showed that
there is excess risk of severe PPH with misoprostol (3.3% vs 2.4%; RR
1.33, 95% CI, 1.16–1.52) although misoprostol demonstrated a trend
toward lowered risk of blood transfusion (RR 0.84; 95% CI, 0.66–1.06)
[22]. There was no difference between the comparison groups with
respect to other indicators of blood loss severity such as the use of
additional uterotonics, postpartum hemoglobin, and manual removal
of the placenta. Misoprostol was associated with signiﬁcantly increased
adverse effects, notably severe shivering (RR 7.24; 95% CI, 4.74–11.08)
and pyrexia (≥38 degrees) (RR 6.68; 95% CI, 3.74–11.93). While
these trials were essentially hospital based, the quality of the evidence
is sufﬁcient to discourage further studies on this question in any
other setting.
4. Should lower-level caregivers administer misoprostol to:
(a) prevent; and (b) treat PPH in a community setting?
One of the main advantages of misoprostol over the conventional
uterotonics is that it is available in tablet form and thus can be
administered by less-skilled providers. The recommended dose for
PPH prevention and treatment is not dependent on the woman's
weight and can easily be speciﬁed in terms of the number of tablets at
the dispensing point. A large systematic review of lay health workers'Fig. 5. Randomized trials of the effect of 600 μg of oral or sublingual misoprostol versus plac
care settings, subgrouped by the third stage of labor practice.delivery of health interventions to improve maternal, newborn, and
child outcomes did not identify any studies that assessed the effects
of lay health workers or trained traditional birth attendants (TBAs)
administering misoprostol for PPH prevention or treatment com-
pared with other cadres or no care [23]. However, two of the trials
that demonstrated the positive effects of oral misoprostol compared
with placebo in a community setting provide indirect evidence that
trained TBAs and auxiliary nurse midwives could safely administer
misoprostol for PPH prevention with good effects [17,18]. A double-
blind randomized controlled trial from rural Gambia where trained
TBAs provided either oral misoprostol or 0.2 mg ergometrine for PPH
prevention at home births also supports this indirect evidence [24].
While these trials did not assess the effectiveness of lower-level
caregivers' use of misoprostol for PPH prevention compared with
other cadre or no approach, it is reassuring that they showed no
adverse events attributable to this service delivery model. In addition,
unlike the parenteral method of administration that could by itself
compromise drug effectiveness or cause complications when given
without necessary skills and precautions, the oral method poses no
speciﬁc danger. Given that there are no concerns about lay health
workers' need to make any diagnosis to use misoprostol for PPH
prevention or the need for special skills to identify and manage its
potential adverse effects, the indirect evidence sufﬁces in guiding future
recommendations and policy formulation. These explanations should
provide enough conﬁdence for the international health communityebo on severe postpartum hemorrhage (blood loss >1000 mL) in community/primary
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administering misoprostol for PPH prevention. Recent developments
suggest that this service delivery model is becoming increasingly
acceptable by stakeholders and it is likely that the use ofmisoprostol by
community healthcare providers and trained lay health workers would
soon feature in international recommendations for PPH prevention.
For PPH treatment, there is no direct evidence on the effectiveness
or acceptability of using lay health workers to administer misoprostol
compared with usual care. There is also no reliable indirect evidence
as the ﬁndings supporting the value of misoprostol in treating
hemorrhage were conducted in hospitals with skilled professionals.
The main concern with using this approach relates to the need for
skill to accurately diagnose atonic PPH by lower-level providers,
which cannot be guaranteed even with training. In a ﬁeld interven-
tion trial in Kigoma, Tanzania, TBAs were trained to diagnose PPH
(using a locally adapted measure that roughly estimated blood loss)
and treat with 1000 μg of rectal misoprostol [25]. These TBAs were
reported to diagnose PPH satisfactorily at both comparison sites and
those in intervention sites used rectal misoprostol to effectively treat
PPH with consequent reduction in referral to a health facility. The
study provides somewhat indirect and context-speciﬁc evidence on
trained lower-level caregivers' potential to use misoprostol for PPH
treatment. For it to be applicable and useful to other settings, this
crude assessment of PPH by lay caregivers ﬁrst needs to be validated.
While it appears plausible that the desirable consequences of less-
trained caregivers using misoprostol for PPH treatment probably
outweighs the undesirable results, concerns about misguided delays
in referral for non-atonic PPH are likely to remain an obstacle to
international acceptance of this model for improving women's
survival. Although this model may be acceptable and feasible under
certain conditions, it might be wise at the moment to consider
this option only in the context of rigorous research in places where
an effective lay caregivers' program with a vibrant referral system
already exist and where misoprostol use can be closely monitored
with relevant indicators.
5. Should misoprostol be distributed to women during prenatal
care for self-administration following childbirth?
The growing body of research demonstrating the effectiveness
of misoprostol for PPH prevention in the community setting has
paved the way for evaluation of different service delivery models to
maximize its potential in underserved populations. Perhaps the most
controversial of these operational techniques is advance community
distribution of misoprostol to prenatal women for self-administration
following childbirth. This strategy was borne out of the fact that as a
result of cultural, physical, or geographical barriers to access to skilled
delivery care, many pregnant women in remote and rural hard-to-
reach areas of the world would deliver at home in the presence of a
family member or at most an unskilled attendant. Advance provision
of misoprostol to pregnant women themselves for self-administration
has the potential to save lives where no uterotonic coverage exists,
but also risks inappropriate use before birth or for other indications.
To date, there are two published studies that have evaluated
the beneﬁts and potential risks of community distribution of miso-
prostol for PPH prevention by self-administration. The ﬁrst was a
“nonrandomized, community experimental control study” in rural
Afghanistan that evaluated the feasibility, acceptability, and pro-
grammatic effectiveness of a strategy of community education on PPH
prevention accompanied by advance provision of misoprostol directly
to prenatal women for self-administration following childbirth [6].
The second was an uncontrolled before–after operation research
in Nepal that investigated the feasibility, acceptability, and safety of
community-based distribution of misoprostol to pregnant women
[5]. The two studies demonstrated that acceptance and self-use of
misoprostol for PPH prevention by a large number of pregnant womenare feasible. They also showed that incorrect use or misuse is extremely
rare (b1%) and that over 60% increase in uterotonic coverage
(misoprostol plus oxytocin) can be achieved through the strategy.
These studies have been the basis for implementing similar programs in
other countries such as India, Indonesia, Kenya, Mozambique, Nigeria,
and Tanzania.
However, making recommendations on health system policies
according to current standards requires the consideration of the quality
of evidence on priority outcomes, magnitude of effects, balance
between beneﬁts and harms, values and preferences, and resource
use, in addition to the feasibility of the intervention (the GRADE
approach). A recent Cochrane review assessing the beneﬁts and risks of
a strategy of advance community distribution of misoprostol identiﬁed
no randomized or quasi-randomized trials to support this strategy
of rolling out misoprostol [26]. As nonrandomized studies can also
provide good evidence, particularly where the research question
poses signiﬁcant logistical and ﬁnancial challenges to be explored in
a randomized trial, an assessment of the Afghanistan and Nepal
studies is important to understand whether they are sufﬁcient to
drive policies. Evaluation of the characteristics for the two studies (not
shown) indicated that the community interventions were robust and
outcomemeasures of interestwere essentially important feasibility and
programmatic effectiveness outcomes. Both studies did not set out to
assess misoprostol efﬁcacy in the context of advance distribution and
therefore did not objectively report outcomes related to blood loss or
other indicators of severe morbidity. Although both studies provided
information on adverse events and maternal death, only the Nepal
study included maternal death as part of safety outcomes a priori.
Assessment of the risk of bias (not shown) indicated that as a result of
the inherent limitations of their designs, both studies were at high risk
of bias at multiple levels. Using the GRADE approach, study limitations
such as high risk of selection and confounding biases and potential
effects of unmeasured co-interventions as identiﬁed in these studies
are likely to generate between “low” to “very low” quality evidence
for the relevant outcomes and may likely weaken the strength of the
corresponding recommendation.
The two studies were conceived against the background of
misoprostol's proven effectiveness and safety in the community and
therefore disregarded some priority outcomes that are also critical for
decision making for women, clinicians, and policy makers. This
concept assumed that misoprostol administered by trained caregivers
(as in the community misoprostol trials) is as effective and safe as
that self-administered by the woman herself immediately after
childbirth. This assumption may not be true as it ignores the potential
effects of the “advance distribution” and “self-administration” com-
ponents of the intervention as well as the problems that could arise if
the woman develops adverse effects. An individually randomized
placebo-controlled trial of advance distribution of misoprostol is
currently in progress to clarify these issues. What is clear at the
moment is that the strategy of advance distribution in resource-poor
settings is effective in ensuring a dramatic increase in the proportion of
women having misoprostol available at birth. The beneﬁts regarding
the overall improvement in delivery outcomes for women, however,
remain uncertain given that none of these studies could reliably
demonstrate any effect on severe morbidity or maternal death despite
the large number of women recruited. In view of the huge resources
required to roll out this strategy, it is appropriate to ﬁrst determine
if this approach is better than usual (or standard) care in these settings
at an individual level before testing it in more rigorous community-
level studies.
6. Conclusion
Misoprostol is arguably the most studied drug in sexual and
reproductive health since the early 1990s. Its use for PPH prevention
and treatment is likely to be the most useful, yet this remains its main
110 O.T. Oladapo / International Journal of Gynecology and Obstetrics 119 (2012) 105–110area of controversy. There is now substantial evidence to show that
misoprostol is better than no treatment when used for prevention or
treatment of PPH. Tangible indirect evidence also exists to support
trained lower-level health providers, including TBAs, to safely and
effectively administer misoprostol for PPH prevention. There are still
concerns about the competence of lower-level health providers to
safely diagnose and treat PPH in the community as the evidence base
is weak. While efforts are being made to ascertain how low the skill
level of the birth attendant should be to be able to treat PPH with
misoprostol, it may be wise for the international community to focus
on strategies that ensure that lower-level and lay caregivers are
trained to increase uterotonic coverage for PPH prevention at the
time of birth. As the saying goes, “prevention is better than cure”. In
our global drive to prevent PPH-related sufferings and deaths in the
remote regions of the world, it is the responsibility of the scientiﬁc
community to ensure that international standards of generating and
applying evidence are not compromised. Health equity can only be
achieved by providing interventions with clear beneﬁts to women
who have no power to choose.
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